ZIVO BIOSCIENCE INC - ZIVO STOCK NEWS

ZIVO Bioscience, Inc. (NASDAQ: ZIVO) has appointed John B. Payne as President and CEO, succeeding Andrew A. Dahl. Payne, who has served on the Board since July 2013, expressed his enthusiasm for leading the company and emphasized the importance of its algae technology and management team. The Board highlighted Payne's extensive experience in the veterinary sector and his skills in managing growth businesses as vital for ZIVO's future. The company is focused on developing therapeutic and nutritional products from proprietary algal cultures.

Zivo Bioscience, Inc. (NASDAQ: ZIVO, ZIVOW) announced that CEO Andrew A. Dahl will present at the Global AgTech Virtual Conference on October 14, 2021, at 10 a.m. EDT. Dahl will speak during the Health and Wellness Panel. The conference features multiple panels with executives from the AgTech sector and a keynote speech by Ambassador Kip E. Tom, CEO of Tom Farms. Participants can attend the conference by signing up as M-Vest members. Zivo focuses on developing therapeutic products derived from proprietary algal cultures.

Zivo Bioscience, Inc. (NASDAQ: ZIVO, ZIVOW) has announced its annual shareholder meeting scheduled for October 12, 2021, at 9:00 a.m. EST. The meeting will be held virtually and in-person due to COVID-19 health concerns. Shareholders are directed to use their proxy card for Control IDs to participate, while the general public can use a standard Control ID of 000000000. Relevant proxy statements can be accessed via the provided links. Zivo specializes in developing therapeutic products derived from proprietary algal cultures for various health applications.

Zivo Bioscience, Inc. (NASDAQ: ZIVO, ZIVOW) announced significant progress in their financial and product development in a recent shareholder letter. The company successfully completed a capital raise of $12.2 million after its Nasdaq up-listing, enhancing its financial resources for R&D in biotech and agtech. Ongoing studies in poultry gut health and algal biomass applications are underway, indicating a commitment to innovation. They are also expanding operations in multiple locations, addressing COVID-related delays, and exploring new product potentials in health markets.

Zivo Bioscience, Inc. (NASDAQ: ZIVO), a biotech/agtech company, announced that CEO Andrew Dahl will present at two upcoming virtual investor conferences. He will speak at the Q3 Investor Summit on August 17, 2021, at 9:30 am ET, and at the SNN Network Summer Virtual Event on August 19, 2021, also at 9:30 am ET. Management will be available for one-on-one meetings during both events. Investors can register through the provided links. Zivo focuses on developing therapeutic and nutritional products from proprietary algal cultures for health benefits.

Zivo Bioscience, Inc. (NASDAQ: ZIVO, ZIVOW) announced the closing of the sale of an additional 150,000 shares of common stock at $4.99 per share, generating gross proceeds of approximately $748,500. This follows the partial exercise of the underwriters’ over-allotment option related to its public offering that closed on June 2, 2021. The offering was managed by Maxim Group LLC and Joseph Gunnar & Co., LLC. The shares were sold under the registration statements filed with the SEC. Zivo specializes in developing bioactive compounds derived from proprietary algal cultures for medicinal and nutritional applications.

ZIVO Bioscience, Inc. (NASDAQ: ZIVO), a Michigan-based biotech/agtech firm, will be presenting at the LD Micro Virtual Invitational Conference from June 8-10, 2021. CEO Andrew Dahl is scheduled to deliver a corporate overview on June 9 at 6:00 PM ET, Track 3. Investors can register to view the presentation online. ZIVO focuses on developing therapeutic and nutritional bioproducts from proprietary algal cultures, targeting immune health and functional food ingredients. The company's products aim to enhance immune response and reduce contamination in poultry.

Zivo Bioscience, Inc. (NASDAQ: ZIVO, ZIVOW) announced the closing of its public offering of 2,760,000 units at $5.00 each, generating approximately $13.8 million in gross proceeds. Each unit includes one share of common stock and one warrant priced at $5.50. Following a 1-for-80 reverse stock split effective May 28, 2021, the common stock and warrants trade separately on Nasdaq. Additionally, underwriters have a 45-day option to purchase up to 414,000 shares and/or warrants.

Zivo Bioscience, Inc. (OTCMKTS:ZIVO) announced an upsized public offering of 2,760,000 units priced at $5.00 per unit, expected to generate $13.8 million before expenses. Each unit comprises one share of common stock and one warrant, with the warrants exercisable at $5.50. The offering will close on June 2, 2021, and follows a 1-for-80 reverse stock split effective May 28, 2021. ZIVO has granted underwriters a 45-day option to purchase additional units for over-allotments. Trading on Nasdaq is set to commence on May 28, 2021.